Neuroprotection by Transgenic Expression of Glucose-6-phosphate Dehydrogenase in Dopaminergic Nigrostriatal Neurons of Mice.
From: Laboratorio de Investigaciones Biomédicas, Hospital Universitario Virgen del Rocío, E-41013 Sevilla, Spain.
The Journal of neuroscience : the official journal of the Society for Neuroscience
- Publish Date: Apr 2006
- ISSN: 1529-2401
- Volume: 26
- Issue: 17
- Pages: 4500-8
- Medium: Internet
- Language: English
- Citation (JAMA): Mejías Rebeca, Villadiego Javier, Pintado C Oscar, et al. Neuroprotection by Transgenic Expression of Glucose-6-phosphate Dehydrogenase in Dopaminergic Nigrostriatal Neurons of Mice.. J. Neurosci. Apr 2006;26:4500-8
Abstract
Oxidative damage to dopaminergic nigrostriatal (DNS) neurons plays a central role in the pathogenesis of Parkinson’s disease (PD). Glucose-6-phosphate dehydrogenase (G6PD) is a key cytoprotective enzyme that provides NADPH, the major source of the reducing equivalents of a cell. Mutations of this enzyme are the most common enzymopathies worldwide. We have studied in vivo the role of G6PD overexpressed specifically in the DNS pathway and show that the increase of G6PD activity in the soma and axon terminals of DNS neurons, separately from other neurons or glial cells, protects them from parkinsonism. Analysis of DNS neurons by histological, neurochemical, and functional methods showed that even a moderate increase of G6PD activity rendered transgenic mice more resistant than control littermates to the toxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The neuroprotective action of G6PD was also observed in aged animals despite that they had a greater susceptibility to MPTP. Therefore, overexpression of G6PD in dopaminergic neurons or pharmacological activation of the native enzyme should be considered as potential therapeutic strategies to PD.
Mesh Headings (Keywords): Animals, Animals, Genetically Modified, Cells, Cultured, Corpus Striatum, Dopamine, Glucosephosphate Dehydrogenase, Mice, Neuroprotective Agents, Parkinsonian Disorders, Recombinant Proteins, Substantia Nigra
Check for Full Text / PubMed Unique Identifier (PMID): 16641229
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.